Coherus BioSciences announces unexpected death of board member Alan C. Mendelson

Coherus Oncology, Inc.

Alan C. Mendelson passed away unexpectedly on October 8, 2021.
He served as a director since January 2021 and as external legal counsel since Coherus' founding in 2010.
Mendelson was a partner at Latham & Watkins and Cooley, and acted as general counsel at Amgen and Cadence.
He served on boards of several public biotech companies including Aviron, CV Therapeutics, and QLT.
CEO Denny Lanfear expressed condolences, noting Mendelson's profound impact on the company and industry.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alan C. Mendelson

Director

CHRS · Coherus Oncology, Inc.

Effective: 2021-10-08
Filed: October 13, 2021, 7:59 PM ET

deeply regrets to announce that Alan C. Mendelson, a member of the Company’s Board of Directors, unexpectedly passed away on Friday, October 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan C. Mendelson departed as Director at Coherus Oncology, Inc..

Action: passed away
Role: Director

Exact text from the filing

deeply regrets to announce that Alan C. Mendelson, a member of the Company’s Board of Directors, unexpectedly passed away on Friday, October 8, 2021.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-297915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.